SCHEMBL757793

SCHEMBL757793

CCS(=O)(=O)NCC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
CYP3A4 P08684 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPK1 P28482 2/20 0.52
MAPT P10636 2/20 0.52
ALOX15 P16050 1/20 0.52
CES1 P23141 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
LMNA P02545 1/20 0.51
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
PTPN1 P18031 2/20 0.46
ERCC5 P28715 1/20 0.46
FEN1 P39748 1/20 0.46
ALDH1A1 P00352 6/20 0.45
AGTR1 P30556 2/20 0.45
CYP1A2 P05177 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754844 0.85 KMT2A (0.56) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL5320468 0.84 MMP1 (0.56) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL754846 0.84 ALDH1A1 (0.52) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL11323836 0.81 HPGD (0.56) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL5899545 0.80 CA1 (0.55) MEN1KMT2AMAPK1MAPTALOX15
SCHEMBL3635917 0.80 HPGD (0.46) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL28413400 0.79 MEN1 (0.54) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL5899544 0.78 KAT6A (0.58) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL10859743 0.78 KMT2A (0.57) HPGDMEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL5899484 0.77 ALDH1A1 (0.50) HPGDMEN1KMT2ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
EP-1847534-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2012-03-21 EP disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
EP-1847534-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-06-22 EP disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20100240716-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-09-23 US disclosed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-7759371-B2 Thiadiazoline derivative Kyowa Hakko Kinn Co., Ltd. (JP) 2010-07-20 US disclosed
US-7425636-B2 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-09-16 US disclosed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 HPGD 1841/4885MEN1 2153/4885KMT2A 558/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B HPGD 3533/4885MEN1 3155/4885KMT2A 514/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 HPGD 1841/4885MEN1 2153/4885KMT2A 558/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B HPGD 3533/4885MEN1 3155/4885KMT2A 514/4885
US-20100240716-A1 THIADIAZOLINE DERIVATIVE BRWD1, WDR82, RB1 HPGD 1751/4885MEN1 2027/4885KMT2A 665/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 HPGD 1841/4885MEN1 2153/4885KMT2A 558/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B HPGD 3533/4885MEN1 3155/4885KMT2A 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.